INSECTICID2024-10-012024-12-31 INSECTICID2024-10-012024-12-31 INSECTICID2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member INSECTICID2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member INSECTICID2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532851 INSECTICID NA Insecticides (India) Limited Equity 2024-04-01 2025-03-31 2025-02-10 2024-12-27 INR Lakhs Third quarter 14:00:00 15:30:00 2025-02-10 2025-02-10 Not applicable Single segment Agro-chemicals 2024-10-01 2024-12-31 Unaudited Standalone 3592271000.00 2092000.00 3594363000.00 2393705000.00 209511000.00 -274408000.00 321115000.00 14038000.00 75498000.00 655545000.00 3395004000.00 199359000.00 0.00 199359000.00 50859000.00 -1514000.00 49345000.00 0.00 150014000.00 0.00 0.00 0.00 0.00 150014000.00 -7004000.00 143010000.00 0.00 0.00 290978000.00 10 5.15 5.15 0.00 0.00 5.15 5.15 1. The above Standalone Unaudited Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2025. The Joint Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com. 2. The above Standalone Unaudited Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ( the Act ), as applicable and guidelines issued by the Securities and Exchange Board of India ( SEBI ). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto. 3. The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz Agro-Chemicals comprising of Technical & Formulation. 4. The Board of Directors of the Company at its meeting held on August 30, 2024, approved Buyback of 5,00,000 fully paid-up equity shares of face value of Rs. 10/- each at a price of Rs. 1000/- per equity share (being 1.69% of the total paid up equity capital of the Company) for an aggregate consideration not exceeding Rs. 5,000 Lacs (excluding transaction cost and any other expenses incurred for the buy back) representing 4.97% and 4.96% of the aggregate of the paid up share capital and free reserves (including securities premium) as per the audited standalone and consolidated financial statements respectively as on March 31, 2024. Further, on the settlement date i.e. September 30, 2024, Company has made payment of Rs. 5,000 Lacs to those shareholders of securities whose offer has been accepted. The issued capital of the Company pre-buyback was 2,95,97,837 and post-buyback is 2,90,97,837. However, as on September 30, 2024, the number of shares remain 2,95,97,837 as the same were extinguished on October 05, 2024. In accordance with section 69 of the Companies Act, 2013, the Company has created ‘Capital Redemption Reserve’ of Rs. 50 Lacs equal to the nominal value of the shares bought back as an appropriation from general reserve. 5. The Board of Directors of Insecticides (India) Limited at its meeting held on August 09, 2024 had approved the dissolution/ liquidation of its wholly owned subsidiary IIL Overseas DMCC, Dubai. Accordingly, IIL Overseas DMCC has filed the application for windup / dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) for which approval is yet to be received as of December 31, 2024. 6. The Board of Directors of the Company, at its meeting held on November 11, 2024, approved the acquisition of Kaeros Research Private Limited (“Target Company”) from its existing shareholders through a share purchase agreement (“the Scheme” or “SPA”) between the existing shareholders and the Company. The Company has entered into an SPA with the existing shareholders as of November 11, 2024, and 100% of the shares have been transferred to the Company. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 16431207000.00 42904000.00 16474111000.00 10278296000.00 629172000.00 471036000.00 1090042000.00 47055000.00 219113000.00 2059061000.00 14793775000.00 1680336000.00 0.00 1680336000.00 431672000.00 -8743000.00 422929000.00 0.00 1257407000.00 0.00 0.00 0.00 0.00 1257407000.00 -5034000.00 1252373000.00 0.00 0.00 290978000.00 10 42.71 42.71 0.00 0.00 42.71 42.71 Other Expenses 655545000.00 Other Expenses 2059061000.00 -7004000.00 -5034000.00 0.00 0.00 0.00 0.00